TaiMed announced today that the first patient has been successfully enrolled  in a phase 2a clinical study evaluating the bi-monthly injection of the  TMB-365 and TMB-380 combination for HIV therapy. This study aims to gather  information regarding the efficacy, safety, and pharmacokinetics of the dual  antibody combination for maintenance therapy. Such data will serve as a  crucial reference for designing future clinical trials.
The target patient group for this study comprises HIV patients who have  already achieved viral load suppression through first or second-line  therapies and have transitioned to TMB-365/380 combination therapy without  the concurrent use of other HIV drugs. Both TMB-365 and TMB-380 are   monoclonal antibodies designed to provide long-lasting effects in the treatment of HIV patients.
Should the trial proceed according to the plan, preliminary results are  expected to be available by the end of 2024.